Is Mersana Therapeutics, Inc. (MRSN) a Buy, Sell, or Hold?
Mersana Therapeutics, Inc.
NASDAQ:MRSN
$29.08 USD
$0 (0.0%)
- Volume
- 624.02K
- Average Volume
- 135.97K
- Market Capitalization
- $145.36M
- P/E Ratio
- -2.59
- Dividend Yield
- 0.00%
- Price Target
- $10.00
- Year High
- $30.39
- Year Low
- $5.21
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.39
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Martin H. Huber |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | MRSN |
| CUSIP | 59045L205 |
| CIK | 0001442836 |
| Web | https://www.mersana.com |
| Phone | 617 498 0020 |
| Currency | USD |
| Employees | 102 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | -0.04 |
| Payout Ratio | 0.00 |
| Current Ratio | 1.39 |
| Quick Ratio | 1.39 |
| Cash Ratio | 1.30 |
Sales & Book Value
| Annual Sales | $40.5M |
| Price / Sales | 8.64 |
| Cash Flow | -11.05 |
| Price / Cash Flow | -2.64 |
| Price / Book | -2.44 |
Price Target and Rating
| Average Stock Price Forecast | $10.00 |
| High Stock Price Forecast | $17.00 |
| Low Stock Price Forecast | $3.00 |
| Forecast Upside/Downside | 190.80% |
| Consensus Rating | N/A |
| Rating Score(0-5) | 0 |
| Research Coverage | 19 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-14.12 |
| Trailing P/E Ratio | -2.59 |
| PEG Ratio | -0.35 |
| P/E Growth | -0.35 |
| Net Income | $-69.19M |
| Net Margin | -332.74% |
| Pretax Margin | -332.74% |
| Return on Equity | 116.96% |
| Return on Assets | -89.28% |
Financials Score
| AltmanZ Score | -23.23 |
| Piotroski Score | 2.00 |
| Working Capital | 16.72M |
| Total Assets | 62.69M |
| Ebit | -67.34M |
| Market Cap | 145.36M |
| Total Liabilities | 122.22M |
Poll Results
About Mersana Therapeutics, Inc. (NASDAQ:MRSN) Stock
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to pioneering novel antibody-drug conjugates (ADCs) for cancer patients with pressing unmet medical needs. Their flagship product candidate, XMT-1592, a Dolasynthen ADC engineered to target NaPi2b-expressing tumor cells, is presently undergoing Phase I clinical evaluation for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company's development pipeline also includes XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate, and XMT-2056, an Immunosynthen development candidate. Additionally, Mersana maintains strategic research and development collaborations with Merck KGaA and Asana BioSciences, LLC for the creation of ADC product candidates, leveraging its Fleximer technology. Incorporated in 2001 ... , the company initially operated as Nanopharma Corp. before rebranding as Mersana Therapeutics, Inc. in November 2005, and is headquartered in Cambridge, Massachusetts.
Frequently Asked Questions
-
What is the current Mersana Therapeutics, Inc. (MRSN) stock price?
-
Mersana Therapeutics, Inc.(NASDAQ:MRSN) stock price is $29.08 in the last trading session. During the trading session, MRSN stock reached the peak price of $30.39 while $5.21 was the lowest point it dropped to. The percentage change in MRSN stock occurred in the recent session was 0.0% while the dollar amount for the price change in MRSN stock was $0.
-
MRSN's industry and sector of operation?
-
The NASDAQ listed MRSN is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of MRSN?
-
Brian C. DeSchuytner | Senior Vice President, Chief Financial Officer & Chief Operating Officer
Martin H. Huber | President, Chief Executive Officer & Director
Timothy Lowinger | Senior Vice President and Chief Science & Technology Officer
Marc Damelin | Exe. Director and Head of Biology, Oncology, Antibody-Drug Conjugate ADC Discovery & Develop.
Chuck Miller | Senior Vice President of Regulatory Affairs -
How many employees does MRSN have?
-
Number of MRSN employees currently stands at 102. MRSN operates from 840 Memorial Drive, Cambridge, MA 02139, US.
-
Link for MRSN official website?
-
Official Website of MRSN is: https://www.mersana.com
-
How do I contact MRSN?
-
MRSN could be contacted at phone #617 498 0020 and can also be accessed through its website. MRSN operates from 840 Memorial Drive, Cambridge, MA 02139, US.
-
How many shares of MRSN are traded daily?
-
The average number of MRSN shares traded daily for last 3 months was 135.97K.
-
What is the market cap of MRSN currently?
-
The market value of MRSN currently stands at $145.36M with its latest stock price at $29.08